Morphic partners with investor AbbVie on integrin inhibitor development
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
Morphic raises $80M in Series B round to fund oral integrin inhibitor development
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.